https://doi.org/10.55788/a127cfc0
Dr Tomas Vetrovsky (Charles University, Czechia) and colleagues performed a multicentre, randomised, controlled study (NCT03041610) to assess the effect of a 6-month lifestyle walking intervention on functional capacity in patients with HFrEF [1]. The 202 participants were randomised 1:1 to usual care or the walking intervention. The intervention included behaviour change techniques, self-monitoring of daily step count with a wrist-worn wearable device, recording daily steps in a paper diary, goal setting, and phone counselling sessions. The primary outcome was the difference in walking distance, measured by a 6-minute walk test at 6 months.
At 6 months, no significant difference was observed between the control group and the experimental group in the primary outcome, with an adjusted between-group difference of 7.4 meters, numerically favouring the experimental group (95% CI -8.0 to 22.7; P=0.35). “Nonetheless, from baseline, the average daily step count was increased in the intervention group (+790 steps) and decreased in the control group (-667 steps). This difference was significant,” according to Dr Vetrovsky (difference 1,420 steps; 95% CI 749–2,091).
Similarly, the number of daily minutes of moderate to vigorous physical activity was increased in the intervention arm compared with the control arm (adjusted difference 8.2 minutes; 95% CI 3.0–13.3). Moreover, participants in the intervention arm reported an improvement in SF-36 ‘general health’ score, assessing health-related quality of life, compared with those in the control arm (adjusted difference 4.5; 95% CI 0.7–8.4). Other areas of the SF-36 and other secondary outcomes did not reveal differences between the 2 groups at 6 months.
“The increased walking activity that we observed in the intervention arm was not associated with an improvement in functional capacity,” concluded Dr Vetrovsky. “Further research is needed to understand why increased physical activity does not lead to improved functional outcomes in this population.”
- Vetrovsky T, et al. Lifestyle walking intervention in patients with HFrEF: the WATCHFUL trial. FS06, AHA Scientific Sessions 2023, 11–13 November, Philadelphia, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Head-to-head: Surgical embolectomy versus ultrasound-assisted thrombolysis in high-risk pulmonary embolism Next Article
Successful results for semaglutide in the highly anticipated SELECT trial »
« Head-to-head: Surgical embolectomy versus ultrasound-assisted thrombolysis in high-risk pulmonary embolism Next Article
Successful results for semaglutide in the highly anticipated SELECT trial »
Table of Contents: AHA 2023
Featured articles
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Hot Topics in CAD/PAD
MINT: Liberal or restrictive transfusion strategy in MI with anaemia?
ORBITA-2 confirms PCI effective for symptom relief in patients with stable angina
Nicotinamide riboside shows promising trend for walking function in PAD
Pemafibrate reduces microvascular complications of PAD and T2D
Dapagliflozin improves cardiometabolic outcomes in myocardial infarction
Optimising Hypertension Outcomes
Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension
Sodium intake and blood pressure: new insights
Post-partum intervention lowers BP after hypertensive pregnancy
Biannual zilebesiran associated with substantial BP reductions
Future of Lipid-Lowering Therapies
Encouraging data for lepodisiran as Lp(a) lowering therapy
Gene editing may change the treatment landscape of hypercholesterolaemia
REPRIEVE: Mechanisms behind MACE reduction in HIV population on pitavastatin
Recaticimab may offer a solution for uncontrolled hypercholesterolaemia
Atrial Fibrillation and Sudden Cardiac Death
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Liraglutide may improve post-ablation outcomes in obese patients with AF
Single or dual cardioversion in patients with obesity and AF?
NOAH-AFNET 6: Does the duration of AHRE influence response to edoxaban?
ARTESIA: How useful is anticoagulation in subclinical AF?
Jewel IDE: High compliance rates for novel patch wearable cardioverter defibrillator
Sudden cardiac death in athletes: incidence, causes, and trends over 20 years
Miscellaneous Trials
Successful results for semaglutide in the highly anticipated SELECT trial
Can a walking intervention improve functional status and quality of life in HFrEF?
Head-to-head: Surgical embolectomy versus ultrasound-assisted thrombolysis in high-risk pulmonary embolism
Related Articles
October 30, 2023
Results of FRAIL-AF trial suggest increased bleeding risk with DOACs
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com